STAAR reports prelim Q4 sales $64M, FY22 ICL sales $270M; FY23 outlook $340M

STAAR SURGICAL CO

2023-Q3 EPS reported $0.80 revenue$284,391,000

Preliminary Q4 net sales ~$64M; FY2022 net sales ~$284M (ICL $270M, other $14M).
ICL unit growth 20% Q4 Y/Y, 33% FY2022 Y/Y; U.S. ICL units up 109% Q4 Y/Y.
FY2023 net sales outlook ~$340M, representing ~25% ICL sales growth over FY2022.
Cash and equivalents ~$225M, up from $120M three years ago.
Full FY2022 results expected on/about February 22, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STAAR SURGICAL CO reported the fourth quarter and fiscal year ended December 30, 2022 results: revenue approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022. Guidance initiated.

Period: the fourth quarter and fiscal year ended December 30, 2022
Revenue: approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022
Guidance: initiated
Result: preliminary results

Exact text from the filing

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022. Preliminary net sales were approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0001564590-23-000271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.